Sign Up

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

BETHESDA, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the pricing of an underwritten public offering of 4,501,640 shares of its common stock and warrants to purchase up to an aggregate of 2,250,820 shares of its common stock. The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock is $3.11 per set of securities, yielding an effective price of $1.55 per share and $0.01 per warrant. The warrants are being sold at the rate of one warrant for every two shares of common stock. The warrants will have an exercise price of $1.65 per share, are exercisable immediately upon issuance and will expire five years following the date of issuance.

In connection with the offering, Gain has granted the underwriter a 30-day option to purchase up to an additional 15% of shares of common stock and/or warrants to purchase shares of common stock at the public offering price, less underwriting discounts and commissions.

Newbridge Securities Corporation is acting as the sole book-running manager for the offering.

Gain expects to receive aggregate gross proceeds from the offering, excluding the exercise of the underwriter's option, if any, of approximately $7.0 million, excluding underwriting discounts and commissions and other offering-related expenses.

The offering is expected to close on or about July 17, 2025, subject to customary closing conditions.

Gain intends to use the net proceeds from the offering to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases including GBA1 Parkinson's disease and for general corporate purposes.

The securities in the offering ...